West Chester, PA, United States of America

Nabil A Elshourbagy

This inventor holds 27 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Cardiovascular Treatments. Top assignees: Smithkline Beecham Corporation, Shifa Biomedical Corporation, Temple University. Active years: 1997-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nabil A Elshourbagy. Retrieved from https://idiyas.com/inventor/nabil-a-elshourbagy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 4)

% Patents Active = 92.6

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 3.5

ph-index = 4

Forward Citations = 58(Granted Patents)

Location History:

US (1998)
Chester, PA (US) (2017)
West Chester, PA (US) (1997 - 2021)

Company Filing History:

19 out of 2,198

Smithkline Beecham Corporation

patents

6 out of 6

Shifa Biomedical Corporation

4. 3 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2025

Loading Chart...

Areas of Expertise:

Anti-PCSK9

Cardiovascular Diseases

G-Protein Coupled Receptor

Molecular Cloning

Polynucleotides

7TM Receptor

Human Scavenger Receptor

Calcitonin Gene

Urotensin-II Receptor

Axor10

HNFDS78

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12274693 - Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) nano-formulation of compounds and methods of using the same (2025-04-14),

2. 10947220 - Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases (2021-03-16),

3. 10899748 - Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases (2021-01-26),

4. 10259804 - Anti-endothelial lipase compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases (2019-04-16),

5. 10131637 - Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases (2018-11-20),

6. 9682085 - Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases (2017-06-20),

7. 6881827 - Molecular cloning of a 7TM receptor (AXOR34) and screening methods thereof (2005-04-19),

8. 6461836 - Molecular cloning of a 7TM receptor (AxOR34) and screening methods thereof (2002-10-08),

9. 6428982 - Polynucleotides encoding mouse urotensin-II Receptor (UTB-R) (2002-08-06),

10. 6365715 - Human cardiac/brain tolloid-like protein (2002-04-02),

11. 6361967 - Axor10, a g-protein coupled receptor (2002-03-26),

12. 6287801 - Nucleic acids encoding the G-protein coupled receptor HNFDS78 (2001-09-11),

13. 6197931 - Human marco scavenger receptor (2001-03-06),

14. 6180365 - Polynucleotide encoding a Mouse 7-transmembrane GPR43 receptor (2001-01-30),

15. 6174994 - 7TM receptor (H2CAA71) (2001-01-16),

Title: Innovative Contributions of Nabil A. Elshourbagy in Cardiovascular Treatment

Introduction

Nabil A. Elshourbagy is a noteworthy inventor based in West Chester, PA, known for his significant contributions to the field of cardiovascular disease treatment. With a remarkable portfolio of 26 patents, Elshourbagy's innovations focus on enhancing the management and prevention of cardiovascular conditions, specifically through the modulation of cholesterol levels.

Latest Patents

Among his most recent patents are compounds aimed at inhibiting the proprotein convertase subtilisin kexin type 9 (PCSK9), which plays a crucial role in cholesterol regulation. These compounds provide therapeutic methods for reducing low-density lipoprotein cholesterol (LDL-C) levels and are essential in the treatment and prevention of cardiovascular diseases (CVD), including hypercholesterolemia. The inventive methodologies outlined in these patents showcase the potential to revolutionize cardiovascular treatment protocols.

Career Highlights

Throughout his career, Nabil A. Elshourbagy has made significant strides while working with prominent organizations, including SmithKline Beecham Corporation and Shifa Biomedical Corporation. His experiences at these pharmaceutical companies have enabled him to refine his expertise in drug development and innovation, particularly concerning cardiovascular health.

Collaborations

Elshourbagy has collaborated with notable professionals, including Derk J. Bergsma and Usman Shabon. These partnerships have fostered a collaborative environment for innovation, driving forward creative solutions to pressing healthcare challenges related to cardiovascular diseases.

Conclusion

Nabil A. Elshourbagy's extensive patent portfolio and collaborative efforts highlight his pivotal role in advancing cardiovascular treatment. His dedication to developing compounds and methods that address critical health issues exemplifies the impact that innovative thinking can have on patient care and disease management. As new research and therapies emerge, Elshourbagy's contributions remain a vital part of the ongoing fight against cardiovascular diseases.

Profile summary based on public USPTO records.